Can tablet Cadi-OR (ofloxacin 200 mg + ornidazole 500 mg) be co‑administered with amoxicillin?

Can Cadi-OR be Combined with Amoxicillin?

Yes, Cadi-OR (ofloxacin + ornidazole) can be safely combined with amoxicillin based on pharmacokinetic evidence showing no drug interactions, and this combination is actually supported by clinical practice patterns for certain mixed infections.

Pharmacokinetic Safety

The combination is pharmacokinetically safe. Research demonstrates that amoxicillin does not alter the absorption or pharmacokinetics of ofloxacin 1. When these drugs were administered together in healthy volunteers, no interference with drug absorption or metabolism was observed, confirming they can be co-administered without pharmacokinetic concerns.

Clinical Context for Combined Use

When This Combination Makes Sense

This combination provides broad-spectrum coverage against:

• Gram-positive and gram-negative aerobes (from amoxicillin and ofloxacin)
• Anaerobic organisms (from ornidazole)

The combination is particularly relevant for:

• Mixed aerobic-anaerobic infections where you need enhanced coverage beyond what single agents provide
• Intra-abdominal infections: Guidelines support fluoroquinolone-metronidazole combinations as second-line therapy 2. While ornidazole serves a similar anti-anaerobic role as metronidazole, adding amoxicillin could provide additional enterococcal coverage
• Severe odontogenic infections with mixed flora 3

Evidence from Combination Studies

Research on quinolone combinations confirms that adding metronidazole or ornidazole to fluoroquinolones does not affect quinolone pharmacokinetics 4. The study specifically evaluated ofloxacin with metronidazole and ornidazole, showing no drug interactions and maintained antimicrobial activity.

Important Caveats

Antimicrobial Stewardship Concerns

• Avoid unnecessary broad-spectrum coverage: This triple-drug combination should be reserved for documented mixed infections or severe cases where broad coverage is genuinely needed 5, 3
• Source control is primary: For most infections, surgical drainage or definitive treatment is more important than antibiotics 3
• Fluoroquinolone resistance: Ofloxacin should be used judiciously given resistance concerns 2

When NOT to Use This Combination

• Simple infections: For uncomplicated infections, monotherapy with amoxicillin or amoxicillin-clavulanate is preferred 2, 5
• If amoxicillin-clavulanate is available: This single agent often provides adequate coverage for mixed infections without needing triple therapy 2
• Penicillin allergy: Obviously contraindicated if the patient has amoxicillin allergy 6

Safety Monitoring

• Fixed-dose combinations of ofloxacin-ornidazole have been associated with cutaneous drug reactions 7, so monitor for skin eruptions
• Watch for standard fluoroquinolone adverse effects (tendinopathy, QT prolongation)
• Monitor for Clostridioides difficile infection risk with any antibiotic combination 6

Practical Algorithm

Use this combination when:

1. Documented or highly suspected mixed aerobic-anaerobic infection
2. Severe infection requiring broad coverage
3. Failure of first-line narrow-spectrum therapy
4. No access to amoxicillin-clavulanate or other combination agents

Do NOT use when:

1. Mild-moderate infection amenable to narrow-spectrum therapy
2. Source control alone is sufficient
3. Penicillin allergy present
4. Single-agent therapy has not been tried first

The combination is pharmacologically safe but should be clinically justified to avoid unnecessary broad-spectrum antibiotic use and minimize resistance development.